Vildagliptin is a potent and selective, oral hypoglycemic agent that belongs to the class of second-generation dipeptidyl peptidase IV inhibitors (DPP-IV) also known as “incretin enhancers”. The European Medicines Agency (EMEA) has given approval for the use of vildagliptin in combination with other hypoglycemic agents including metformin, sulfonylureas, insulin, pioglitazone and thiazolidinediones. Apart from this Eucreas, which is a single tablet formulation of metformin and vildagliptin has also been approved. The drug seems to include disease-modifying effects on patients with type2 diabetes. Vildagliptin treatment is known for neutral weight and lipid-neutral effects, very low risk of edema and low blood sugar. Moreover, it has been indicated to improve cardiovascular disease in patients with type 2 DM in multiple monotherapies and in combination.

References

Citation

Citation: Monika Kapoor. “Vildagliptin : The Game Changer”. Acta Scientific Paediatrics 1.2 (2020): 02.

Copyright

Copyright: © 2020 Monika Kapoor. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.